Nurix Therapeutics Inc
For the period ended Nov 30, 2024. Filed Jan 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jan 28, 2025
NRIX$16.14+5.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| November 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $109,997 | $54,627 |
| Marketable securities, current | 499,586 | 233,281 |
| Prepaid expenses and other current assets | 9,804 | 7,595 |
| Total current assets | 619,387 | 295,503 |
| Marketable securities, non-current | — | 7,421 |
| Operating lease right-of-use assets | 28,139 | 31,142 |
| Property and equipment, net | 17,757 | 16,808 |
| Restricted cash | 901 | 901 |
| Other assets | 3,159 | 3,823 |
| Total assets | $669,343 | $355,598 |
| Liabilities and stockholdersʼ equity | ||
| Current liabilities: | ||
| Accounts payable | $11,482 | $6,401 |
| Accrued expenses and other current liabilities | 37,994 | 24,970 |
| Operating lease liabilities, current | 8,014 | 7,489 |
| Deferred revenue, current | 38,364 | 48,098 |
| Total current liabilities | 95,854 | 86,958 |
| Operating lease liabilities, net of current portion | 20,289 | 23,125 |
| Deferred revenue, net of current portion | 26,207 | 45,022 |
| Total liabilities | 142,350 | 155,105 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value— 10,000,000 shares authorized as of November 30, 2024 and 2023; no shares issued and outstanding as of November 30, 2024 and 2023 | — | — |
| Common stock, $0.001 par value— 500,000,000 shares authorized as of November 30, 2024 and 2023; 75,870,718 and 48,718,552 shares issued and outstanding as of November 30, 2024 and 2023, respectively | 76 | 49 |
| Additional paid-in capital | 1,265,536 | 746,299 |
| Accumulated other comprehensive income (loss) | 150 | (655) |
| Accumulated deficit | (738,769) | (545,200) |
| Total stockholders’ equity | 526,993 | 200,493 |
| Total liabilities and stockholders’ equity | $669,343 | $355,598 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.